2021
Incidence and characteristics of metastatic intracranial lesions in stage III and IV melanoma: a single institute retrospective analysis
Sandhu MRS, Chiang VL, Tran T, Yu JB, Weiss S, Goldberg S, Aboian M, Kluger HM, Mahajan A. Incidence and characteristics of metastatic intracranial lesions in stage III and IV melanoma: a single institute retrospective analysis. Journal Of Neuro-Oncology 2021, 154: 197-203. PMID: 34351544, DOI: 10.1007/s11060-021-03813-8.Peer-Reviewed Original ResearchMeSH KeywordsBrain NeoplasmsHumansIncidenceMaleMelanomaPrognosisRetrospective StudiesTesticular NeoplasmsConceptsStage IV melanomaMetastatic brain lesionsStage IIIInitial diagnosisTumor RegistryOverall incidenceBrain lesionsBM incidenceSingle-institute retrospective analysisBM developmentBrain metastases incidenceIncidence of BMInstitution's tumor registryStage III patientsTime of diagnosisMetastatic intracranial lesionsCommon genetic mutationsTumor genetic profileGenetic profileBM occurrenceMedian durationAdvanced melanomaSurveillance regimenIII patientsMedian time
2019
Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease
Abu-Sbeih H, Faleck DM, Ricciuti B, Mendelsohn RB, Naqash AR, Cohen JV, Sellers MC, Balaji A, Ben-Betzalel G, Hajir I, Zhang J, Awad MM, Leonardi GC, Johnson DB, Pinato DJ, Owen DH, Weiss SA, Lamberti G, Lythgoe MP, Manuzzi L, Arnold C, Qiao W, Naidoo J, Markel G, Powell N, Yeung SJ, Sharon E, Dougan M, Wang Y. Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease. Journal Of Clinical Oncology 2019, 38: 576-583. PMID: 31800340, PMCID: PMC7030892, DOI: 10.1200/jco.19.01674.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Agents, ImmunologicalFemaleHumansImmunotherapyInflammatory Bowel DiseasesMaleMiddle AgedNeoplasmsRetrospective StudiesConceptsGI adverse eventsInflammatory bowel diseaseImmune checkpoint inhibitor therapyCheckpoint inhibitor therapyImmune checkpoint inhibitorsAdverse eventsCheckpoint inhibitorsBowel diseaseInhibitor therapyAnti-cytotoxic T-lymphocyte antigen-4 therapyTreatment of IBDCytotoxic T-lymphocyte antigen-4T-lymphocyte antigen-4Cell death 1Multivariate logistic regressionImmunotherapy initiationColonic perforationGI eventsDeath-1Ulcerative colitisCrohn's diseaseMedian timeMultivariable analysisRetrospective studySimilar patients
2016
Melanoma brain metastases: correlation of imaging features with genomic markers and patient survival
Bordia R, Zhong H, Lee J, Weiss S, Han SW, Osman I, Jain R. Melanoma brain metastases: correlation of imaging features with genomic markers and patient survival. Journal Of Neuro-Oncology 2016, 131: 341-348. PMID: 27822597, DOI: 10.1007/s11060-016-2305-8.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorBrain NeoplasmsHumansKaplan-Meier EstimateMagnetic Resonance ImagingMelanomaProto-Oncogene Proteins B-rafRetrospective StudiesConceptsMelanoma brain metastasesSignificant prognostic factorsBRAF inhibitor treatmentPercent of lesionsBrain metastasesMedian survivalPrognostic factorsPatient survivalMultiple lesionsInhibitor treatmentT1-weighted hyperintensityBRAF mutation statusT1-weighted hyperintense signalsNumber of lesionsMethods PatientsRetrospective reviewInstitutional databaseLonger survivalHyperintense signalBrain MRIMelanoma metastasesSingle lesionEnhancement patternLarge lesionsLesion size